Detalhe da pesquisa
1.
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Gastroenterology
; 147(1): 132-142.e4, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24704719
2.
Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
Liver Int
; 35(7): 1833-44, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25556540
3.
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
J Hepatol
; 61(4): 761-9, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24882048
4.
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Lancet Gastroenterol Hepatol
; 2(3): 177-188, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28404133